IMP3 and osteosarcoma: One mouse injected subcutaneously with AXT-sh1 cells developed lethal osteosarcoma tumors at 49 days after cell injection, and the Imp3 expression in these tumors was markedly increased compared with the parental AXT-sh1 cells (Figure 5C: left panel).